Zurueck zur Suche

Reporte zur Charge 4N2AB

Verknuepft ueber VAERS_ID mit VAERSDATA, Vax und Symptoms

31Reporte angezeigt
0Todesfaelle
2Hospitalisiert
0Lebensbedrohlich
0Bleibende Schaeden
CA 3 AL 2 NY 2 MA 2 AZ 2 FL 2 NV 1 NC 1 DC 1 CO 1 TX 1 NJ 1

VAERS 1490890

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge 4N2AB

schwer
Staat
AL
Alter
53,0
Geschlecht
M
Eingang
21.07.2021
Impfdatum
21.07.2021
Beginn
21.07.2021
Tage bis Beginn
0,0
Dosis
1
Route/Site
- / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Fall Loss of consciousness Muscle twitching

Symptomtext

About 5 minutes after vaccine patient slowly fell to the ground and lost consciousness. His body slightly twitched but did not observe eye rolling into back of head, or incontinence. Patient stated prior to receiving vaccine he began feeling lightheaded and has a phobia of needles. Has a history of seizures when an adolescent and last seizure was when he was 19 years old.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Loss of consciousness
Hospital-Tage
-
Labordaten
Patient refused being brought to hospital
Aktuelle Erkrankungen
Unknown
Vorgeschichte
Unknown
Andere Medikamente
Unknown
Allergien
Unknown
Vorherige Impfungen
-

VAERS 2225135

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge 4N2AB

moderat
Staat
NY
Alter
52,0
Geschlecht
M
Eingang
09.04.2022
Impfdatum
29.09.2021
Beginn
01.09.2021
Tage bis Beginn
-
Dosis
2
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: ja Disable: unbekannt ER: unbekannt Erholt: nein
Hypertension Vertigo

Symptomtext

High blood pressure; vertigo; This case was reported by a pharmacist via call center representative and described the occurrence of blood pressure high in a male patient who received Herpes zoster (Shingrix) (batch number 4N2AB, expiry date unknown) for prophylaxis. Concomitant products included RECOMBINANT VARICELLA ZOSTER VIRUS SURFACE GLYCOPROTEIN E (SHINGRIX). On 29th September 2021, the patient received the 2nd dose of Shingrix. In September 2021, less than an hour after receiving Shingrix, the patient experienced blood pressure high (serious criteria hospitalization) and vertigo (serious criteria hospitalization). On an unknown date, the outcome of the blood pressure high and vertigo were unknown. It was unknown if the reporter considered the blood pressure high and vertigo to be related to Shingrix. Additional Information: GSK Receipt Date: 06-APR-2022 Reporter's Comments: Pharmacist reported that the patient received the first dose of Shingrix on 7th July 2021. The patient informed by email to the pharmacist that minutes after receiving the 2nd dose of Shingrix he was hospitalized due to vertigo and high blood pressure. The health care professional requested follow up by phone as soon as possible.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Hypertension
Hospital-Tage
-
Labordaten
Test Date: 202109; Test Name: blood pressure; Result Unstructured Data: (Test Result:high,Unit:unknown,Normal Low:,Normal High:); Comments: lab test performed on an unknown date
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
SHINGRIX
Allergien
-
Vorherige Impfungen
-

VAERS 2025467

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge 4n2ab

moderat
Staat
-
Alter
54,0
Geschlecht
F
Eingang
11.01.2022
Impfdatum
09.08.2021
Beginn
10.08.2021
Tage bis Beginn
1,0
Dosis
1
Route/Site
IM / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Condition aggravated Heart rate increased Heart rate irregular

Symptomtext

Patient called on 01/11/2022 to report the pharmacy that she experienced rapid and irregular heart beat the day after she recieved the first shingrix vaccine on 08/09/2021. Patient has stated she has had issues with rapid and irregular heart beat in the past but after the vaccine it was all day which was unusually for her.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Condition aggravated
Hospital-Tage
-
Labordaten
none
Aktuelle Erkrankungen
patient has experienced irregular/rapid heart rate
Vorgeschichte
N/A
Andere Medikamente
N/A
Allergien
sulfa
Vorherige Impfungen
-

VAERS 1931237

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge 4N2AB

moderat
Staat
MA
Alter
68,0
Geschlecht
M
Eingang
08.12.2021
Impfdatum
30.07.2021
Beginn
-
Tage bis Beginn
-
Dosis
2
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Condition aggravated Inappropriate schedule of product administration Infected cyst

Symptomtext

This case was reported by a pharmacist via call center representative and described the occurrence of infected cyst in a 68-year-old male patient who received Herpes zoster (Shingrix) (batch number 4N2AB, expiry date 10th February 2023) for prophylaxis. The patient's past medical history included surgery (Patient underwent surgical incision and draining of cyst post infection). Previously administered products included Shingrix (1st dose received in 5th January 2021 with batch number 2A3ZA and expiry date 14th October 2022). On 30th July 2021, the patient received the 2nd dose of Shingrix. On an unknown date, less than 4 months after receiving Shingrix, the patient experienced infected cyst and drug dose administration interval too long. On an unknown date, the outcome of the infected cyst and drug dose administration interval too long were unknown. It was unknown if the reporter considered the infected cyst to be related to Shingrix. Additional details were reported as follows: This case was reported by the pharmacist. The pharmacist reported the patient developed an infection in a pre-existing cyst after receiving the second dose of Shingrix. The patient received first dose on 5th January 2021 and second dose on 30th July 2021, which led to drug dose administration interval too. The patient underwent surgical incision and drainage of cyst post infection. Upon escalation to 2nd line specialist, HCP stated cyst was removed 8 days later (after Shingrix administration). The reporter consented for follow-up.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Condition aggravated
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
Medical History/Concurrent Conditions: Surgery (Patient underwent surgical incision and draining of cyst post infection)
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2633101

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge 4N2AB

mild
Staat
AZ
Alter
-
Geschlecht
F
Eingang
22.05.2023
Impfdatum
27.04.2023
Beginn
01.05.2023
Tage bis Beginn
4,0
Dosis
2
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Blister Herpes zoster Injection site pain Pain Pruritus Vaccine positive rechallenge

Symptomtext

got moderate Shingles left back /T5 distribution; Pain; patches of blisters; itching; This non-serious case was reported by a consumer via call center representative and described the occurrence of shingles in a 68-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. The patient's past medical history included shingles (PMH - Shingles in 40s / original shingles in my 40s - left back -T5 distribution). Previously administered products included Zostavax with an associated reaction of herpes zoster (received about 15 years ago from reporting and would get verymild attacks of Shingles every few years in different parts of the body) and Shingrix with an associated reaction of herpes zoster (1st dose was received on 15-FEB-2023, refer case US2023AMR071494). Concurrent medical conditions included borderline diabetes and hypertension (mild). Additional patient notes included the patient was in excellent health. No immune compromised illnesses. Concomitant products included metformin and amlodipine. On 27-APR-2023, the patient received the 2nd dose of Shingrix. In MAY-2023, 1 week after receiving Shingrix, the patient experienced shingles (Verbatim: got moderate Shingles left back /T5 distribution), pain (Verbatim: Pain), blister (Verbatim: patches of blisters) and pruritus (Verbatim: itching). Rechallenge with Shingrix was positive. The outcome of the shingles, pain, blister and pruritus were resolving. It was unknown if the reporter considered the shingles, pain, blister and pruritus to be related to Shingrix. It was unknown if the company considered the shingles, pain, blister and pruritus to be related to Shingrix. Linked case(s) involving the same patient: US2023AMR071494 Additional Information: GSK Receipt Date: 17-MAY-2023 After the second vaccine, about 1 week later she got moderate Shingles left back T5 distribution (the same distribution as her original shingles in her 40s) with pain, patches of blisters and itching, still had the largest 2.5 cm patch but was definitely better compared to last week. She did not consult with her primary care physician because she knew the diagnosis and did not particularly thought antivirals were necessary. She did realize that generally, Shingrix vaccine was not associated with actually getting the Shingles, but she had afraid she definitely got it with both vaccines. With both vaccines, she did not experience much of other generalized symptoms (pain at the injection site with the second vaccine). Today (on the day of reporting), she had mentioned to pharmacist about her Shingles episodes after receiving recent Shingrix vaccines as she felt they needed to know. She was just letting GSK know about her experience with Shingrix vaccines just for GSK interest and nothing more. At the end of the day, she was very grateful that Shingrix vaccine was available for all and that hopefully, she would never get Shingles again. The reporter had consented to follow-up.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Injection site pain
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
Borderline diabetes; Hypertension (mild)
Vorgeschichte
Medical History/Concurrent Conditions: Shingles (PMH - Shingles in 40s / original shingles in my 40s - left back -T5 distribution); Comments: the patient was in excellent health. No immune compromised illnesses
Andere Medikamente
METFORMIN; AMLODIPINE
Allergien
-
Vorherige Impfungen
-

VAERS 2236496

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge 4N2AB

mild
Staat
CA
Alter
76,0
Geschlecht
F
Eingang
15.04.2022
Impfdatum
04.04.2022
Beginn
04.04.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Erythema Injection site erythema Injection site swelling Rash pruritic Skin warm Vaccination site pain

Symptomtext

I experienced pain at the site of the vaccination and redness. Over the next seven days I had swelling of my vaccinated arm down to the elbow, as well as an itchy rash and redness of my skin. My arm felt hot to the touch. These symptoms lasted for one week and then disappeared over two days. I used an ointment once for the itching.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Injection site erythema
Hospital-Tage
-
Labordaten
None
Aktuelle Erkrankungen
none
Vorgeschichte
asthma, mitral valve prolapse, hypertension
Andere Medikamente
Dorzolomide eyedrops, Losartan, Hydrochlorothiazide
Allergien
Terramycin, Lisinopril, Atenolol
Vorherige Impfungen
-

VAERS 1975034

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge 4N2AB

mild
Staat
NV
Alter
50,0
Geschlecht
M
Eingang
23.12.2021
Impfdatum
20.08.2021
Beginn
28.08.2021
Tage bis Beginn
8,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Abdominal pain lower Antineutrophil cytoplasmic antibody Antineutrophil cytoplasmic antibody negative Back pain Blood immunoglobulin A increased Blood immunoglobulin G Burning sensation Differential white blood cell count normal Full blood count normal Laboratory test Pain Platelet count normal

Symptomtext

Pain in lower right abdomen began on 8/28/21. It started as a dull throbbing pain and became more pronounced over the ensuing weeks and months. Pain also consists of a burning sensation in lower right abdomen (near the the throbbing pain) and lower right back. Pain and symptoms continue to this day. Cardio exercise 3x/week for 10 minutes with HIIT has not helped. Taking Sulfasalazine 500 mg 3x/day from 11/19/21-12/10/21 didn't help. Taking 2000 mg daily of Saccharomyces cerevisiae var. boulardii starting on 12/11/21 has not helped. Please note: The above 3 courses of action were taken after the 10/28/21 medical tests indicated in Item 1 (Medical tests).

Weitere VAERSDATA-Felder
Praegender Schweregrund
Abdominal pain lower
Hospital-Tage
-
Labordaten
10/28/21 Inflammatory Bowel Disease Differentiation Panel; ANCA Screen: Negative; Myeloperoxidase Antibody: <1.0; Proteinase, Antibody: <1.0; Saccharomyces Cerevisiae AB (ASCA) (IGG): <20.0--- >>>Saccharomyces Cerevisiae AB (ASCA) (IGA): 56.3 H (HIGH); 10/28/21 CBC (Includes Diff/Plt): Normal
Aktuelle Erkrankungen
None
Vorgeschichte
None
Andere Medikamente
Daily Men's Health Formula Multivitamin/Multimineral Supplement; Vitamin D3 1000 IU (x2); Digestive Probiotic
Allergien
Penicillin
Vorherige Impfungen
DTP (tetanus) around age 7 (1970s). Injected arm swelled and had pain. Had to wear a sling over arm until healed. Exact date and

VAERS 1803791

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge 4N2AB

mild
Staat
CA
Alter
-
Geschlecht
F
Eingang
21.10.2021
Impfdatum
01.08.2021
Beginn
13.08.2021
Tage bis Beginn
12,0
Dosis
1
Route/Site
- / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Injection site pruritus Injection site rash Injection site swelling Rash pruritic Rash vesicular Swelling

Symptomtext

Herpes Zoster like rash; raised itchy; itchy rash; This case was reported by a nurse via call center representative and described the occurrence of vesicular rash in a 68-year-old female patient who received Herpes zoster (Shingrix) (batch number 4N2AB, expiry date 10th February 2023) for prophylaxis. In August 2021, the patient received the 1st dose of Shingrix. On 13th August 2021, less than a week after receiving Shingrix, the patient experienced vesicular rash, raised rash and itchy rash. On 18th October 2021, the outcome of the vesicular rash, raised rash and itchy rash were recovered/resolved. It was unknown if the reporter considered the vesicular rash, raised rash and itchy rash to be related to Shingrix. Additional details were reported as follows; This case was reported by the nurse. The age at vaccination was not reported. The adverse event was reported via afterhours voicemail box, exact date of Shingrix vaccination was unknown, reporter just stated "2 months ago" on the recording. The nurse stated that the patient experienced raised itchy bumps, approximately 6 bumps near injection site, herpes zoster like rash 4-5 days following Shingrix vaccine 2 months ago, no systemic effects, fever or illness. No additional details were available. The reporter consented for follow-up. This case linked with US2021215524, US2021215511, reported by the same reporter.; Sender's Comments: US-GLAXOSMITHKLINE-US2021215524:same reporter US-GLAXOSMITHKLINE-US2021215511:same reporter

Weitere VAERSDATA-Felder
Praegender Schweregrund
Injection site pruritus
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 1801369

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge 4N2AB

mild
Staat
CA
Alter
50,0
Geschlecht
F
Eingang
20.10.2021
Impfdatum
15.10.2021
Beginn
16.10.2021
Tage bis Beginn
1,0
Dosis
1
Route/Site
SYR / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Rash Rash erythematous

Symptomtext

Rash on arm that grew over time. Not itchy but is red in color. Put some Cortizone ointment cream on area. Still red after 6 days from shot.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Rash
Hospital-Tage
-
Labordaten
none
Aktuelle Erkrankungen
none
Vorgeschichte
none
Andere Medikamente
none
Allergien
none
Vorherige Impfungen
-

VAERS 1777112

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge 4n2ab

mild
Staat
-
Alter
59,0
Geschlecht
M
Eingang
11.10.2021
Impfdatum
05.10.2021
Beginn
10.10.2021
Tage bis Beginn
5,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: ja Disable: unbekannt ER: unbekannt Erholt: unbekannt
Nausea Unresponsive to stimuli Vomiting

Symptomtext

On 10/5/21 patient got vaccine, his sister came in on 10/11/21 and said patient on 10/5 was nauseated and throwing up. Took dramamine. On 10/10 patient found nonresponsive in his home. Currently hospitalized.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Nausea
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
Diabetes
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 1694627

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge 4N2AB

mild
Staat
AZ
Alter
51,0
Geschlecht
M
Eingang
13.09.2021
Impfdatum
31.08.2021
Beginn
13.09.2021
Tage bis Beginn
13,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Pain in extremity Skin discolouration

Symptomtext

Patient called to let us know that today 9/13/21 he has started to have pain on his arm. He also states that his arm is yellow. Called primary care and made them aware of the adverse events that were relayed to me. I asked the patient if he could call his primary care MD.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Pain in extremity
Hospital-Tage
-
Labordaten
N/A
Aktuelle Erkrankungen
none
Vorgeschichte
N/A
Andere Medikamente
N/A
Allergien
none
Vorherige Impfungen
-

VAERS 1558279

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge 4n2ab

mild
Staat
FL
Alter
66,0
Geschlecht
F
Eingang
14.08.2021
Impfdatum
22.07.2021
Beginn
22.07.2021
Tage bis Beginn
0,0
Dosis
2
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Pain in extremity Peripheral swelling

Symptomtext

Patient reports swelling and pain in arm since dose administered almost one month ago

Weitere VAERSDATA-Felder
Praegender Schweregrund
Pain in extremity
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 1535194

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge 4N2AB

mild
Staat
NC
Alter
53,0
Geschlecht
F
Eingang
08.08.2021
Impfdatum
06.08.2021
Beginn
07.08.2021
Tage bis Beginn
1,0
Dosis
2
Route/Site
SYR / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Abdominal pain Asthenia Diarrhoea Vomiting

Symptomtext

Abdominal pain, vomiting diarrhea weakness

Weitere VAERSDATA-Felder
Praegender Schweregrund
Abdominal pain
Hospital-Tage
-
Labordaten
08/07/2021
Aktuelle Erkrankungen
None
Vorgeschichte
High BP
Andere Medikamente
Olmesartan, Calcium, vitamin D3, and Claritin
Allergien
Percoset
Vorherige Impfungen
-

VAERS 1529589

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge 4N2AB

mild
Staat
FL
Alter
62,0
Geschlecht
M
Eingang
05.08.2021
Impfdatum
19.07.2021
Beginn
21.07.2021
Tage bis Beginn
2,0
Dosis
2
Route/Site
- / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: unbekannt
Blister COVID-19 Inappropriate schedule of product administration Pain Rash SARS-CoV-2 test positive

Symptomtext

On July 19th, 2021, patient received both shingrix and moderna. He then tested positive for covid on Wednesday the 21st . He developed a rash on his back and sides with painful blisters like shingles.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Pain
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
tadalafil 20 mg
Allergien
NKDA
Vorherige Impfungen
-

VAERS 2728706

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge 4N2AB

gering
Staat
-
Alter
68,0
Geschlecht
F
Eingang
29.12.2023
Impfdatum
02.08.2021
Beginn
02.08.2021
Tage bis Beginn
0,0
Dosis
2
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: unbekannt
Unevaluable event

Symptomtext

None stated.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Unevaluable event
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2728688

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge 4N2AB

gering
Staat
-
Alter
56,0
Geschlecht
M
Eingang
29.12.2023
Impfdatum
09.05.2022
Beginn
09.05.2022
Tage bis Beginn
0,0
Dosis
1
Route/Site
IM / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: unbekannt
Unevaluable event

Symptomtext

None stated.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Unevaluable event
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2727594

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge 4N2AB

gering
Staat
DC
Alter
58,0
Geschlecht
F
Eingang
27.12.2023
Impfdatum
05.08.2021
Beginn
05.08.2021
Tage bis Beginn
0,0
Dosis
2
Route/Site
IM / AR
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: unbekannt
Product storage error

Symptomtext

VACCINE FROZEN INSTEAD OF REFRIGERATED

Weitere VAERSDATA-Felder
Praegender Schweregrund
Product storage error
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2725420

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge 4N2AB

gering
Staat
-
Alter
58,0
Geschlecht
F
Eingang
19.12.2023
Impfdatum
28.10.2021
Beginn
28.10.2021
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
IM / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: unbekannt
Product storage error

Symptomtext

VACCINE FROZEN INSTEAD OF REFRIGERATED

Weitere VAERSDATA-Felder
Praegender Schweregrund
Product storage error
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2724441

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge 4N2AB

gering
Staat
-
Alter
69,0
Geschlecht
F
Eingang
15.12.2023
Impfdatum
10.08.2021
Beginn
20.08.2021
Tage bis Beginn
10,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: unbekannt
Product storage error

Symptomtext

Vaccine was frozen instead of refrigerated.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Product storage error
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2723579

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge 4N2AB

gering
Staat
-
Alter
58,0
Geschlecht
F
Eingang
13.12.2023
Impfdatum
05.08.2021
Beginn
05.08.2021
Tage bis Beginn
0,0
Dosis
2
Route/Site
IM / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: unbekannt
Product storage error

Symptomtext

Vaccine was frozen instead of refrigerated.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Product storage error
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2160604

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge 4N2AB

gering
Staat
-
Alter
-
Geschlecht
U
Eingang
05.03.2022
Impfdatum
-
Beginn
-
Tage bis Beginn
-
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Product storage error

Symptomtext

stored in the freezer and vaccinated; This case was reported by a nurse via call center representative and described the occurrence of incorrect storage of drug in an unspecified number of patients who received Herpes zoster (Shingrix) (batch number 4N2AB, expiry date 10th February 2023) for prophylaxis. On an unknown date, the patient received Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced incorrect storage of drug. On an unknown date, the outcome of the incorrect storage of drug was unknown. Additional details were provided as follows: The age at vaccination was not applicable for this report. Nurse reported that, by mistake they had stored Shingrix in the freezer, which led to incorrect storage of drug and some patients were vaccinated as well. No data was available from patients or vaccination dates. The reporter consented to follow up.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Product storage error
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 1849634

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge 4N2AB

gering
Staat
CO
Alter
66,0
Geschlecht
M
Eingang
07.11.2021
Impfdatum
20.10.2021
Beginn
20.10.2021
Tage bis Beginn
0,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: unbekannt
Expired product administered Extra dose administered

Symptomtext

Patient received expired Fluzone (6/30/21) and came back on 10/27 for a new Fluzone vaccine.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Expired product administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 1832306

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge 4n2ab

gering
Staat
AL
Alter
58,0
Geschlecht
F
Eingang
31.10.2021
Impfdatum
29.10.2021
Beginn
29.10.2021
Tage bis Beginn
0,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Extra dose administered Wrong product administered

Symptomtext

patient received flu shot instead of shingles shot (patient has already received a flu shot on 10/20/2021); after receiving the flu shot we realized patient had requested the shingles not flu; patient then proceeded to ask to still get the shingles shot. followed up with patient the next day and she was doing fine

Weitere VAERSDATA-Felder
Praegender Schweregrund
Extra dose administered
Hospital-Tage
-
Labordaten
none
Aktuelle Erkrankungen
none
Vorgeschichte
none
Andere Medikamente
none
Allergien
macrobid and penicillin
Vorherige Impfungen
-

VAERS 1771848

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge 4n2ab

gering
Staat
TX
Alter
73,0
Geschlecht
F
Eingang
08.10.2021
Impfdatum
17.09.2021
Beginn
17.09.2021
Tage bis Beginn
0,0
Dosis
1
Route/Site
IM / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Limb mass

Symptomtext

Patient developed a lump in her arm.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Limb mass
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
n/a
Allergien
sulfa and penicillin
Vorherige Impfungen
-

VAERS 1744958

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge 4N2AB

gering
Staat
NJ
Alter
62,0
Geschlecht
F
Eingang
29.09.2021
Impfdatum
30.08.2021
Beginn
20.09.2021
Tage bis Beginn
21,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Herpes ophthalmic

Symptomtext

Developed Herpes Keratitis about 3 weeks post vaccine.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Herpes ophthalmic
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
not known
Vorgeschichte
no chronic health conditions
Andere Medikamente
not known
Allergien
no known allergies
Vorherige Impfungen
-

VAERS 1683558

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge 4n2ab

gering
Staat
IN
Alter
-
Geschlecht
M
Eingang
08.09.2021
Impfdatum
01.09.2021
Beginn
01.09.2021
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Incorrect dose administered No adverse event Product preparation issue

Symptomtext

Injected with only the adjuvant; Injected with only the adjuvant; This case was reported by a nurse via call center representative and described the occurrence of inappropriate preparation of medication in a male patient who received Herpes zoster (Shingrix) (batch number 4n2ab, expiry date 10th February 2023) for prophylaxis. On 1st September 2021, the patient received Shingrix. On 1st September 2021, unknown after receiving Shingrix, the patient experienced inappropriate preparation of medication and inappropriate dose of vaccine administered. On an unknown date, the outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were unknown. Additional details were provided as follows: The age at vaccination was not reported. The patient received only adjuvant of Shingrix without the powder component which led to inappropriate preparation of medication and inappropriate dose of vaccine administered. No adverse event was reported. No patient's identifiers were provided. The reporter consented to follow up.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Incorrect dose administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 1681399

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge 4n2ab

gering
Staat
NY
Alter
-
Geschlecht
M
Eingang
08.09.2021
Impfdatum
30.08.2021
Beginn
30.08.2021
Tage bis Beginn
0,0
Dosis
1
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Product administered to patient of inappropriate age Wrong product administered

Symptomtext

administered Shingrix to a patient 19 years of age; varicella vaccine was intended to be given; This case was reported by a nurse and described the occurrence of inappropriate age at vaccine administration in a 19-year-old male patient who received Herpes zoster (Shingrix) (batch number 4n2ab, expiry date 10th February 2023) for prophylaxis. On 30th August 2021, the patient received the 1st dose of Shingrix. On 30th August 2021, unknown after receiving Shingrix, the patient experienced inappropriate age at vaccine administration and wrong vaccine administered. On an unknown date, the outcome of the inappropriate age at vaccine administration and wrong vaccine administered were unknown. Additional details were provided as follows: The age at vaccination was not reported. The registered nurse informed that, during the day a nurse practitioner administered Shingrix to a patient 19 years of age when varicella vaccine was intended to be given, which led to inappropriate age at vaccine administration and wrong vaccine administered. The reporter did not consent to follow up.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Product administered to patient of inappropriate age
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 1665372

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge 4N2AB

gering
Staat
NE
Alter
63,0
Geschlecht
F
Eingang
02.09.2021
Impfdatum
05.04.2021
Beginn
05.04.2021
Tage bis Beginn
0,0
Dosis
3
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Extra dose administered

Symptomtext

Administered third dose; First dose given 02/03/2020 and second dose; This case was reported by a nurse via call center representative and described the occurrence of extra dose administered in a 63-year-old female patient who received Herpes zoster (Shingrix) (batch number 4N2AB, expiry date 10th February 2023) for prophylaxis. Co-suspect products included Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix vaccine (1st dose received on 3rd February 2020). On 25th August 2021, the patient received the 3rd dose of Shingrix. On 5th April 2021, the patient received the 2nd dose of Shingrix. On 5th April 2021, not applicable after receiving Shingrix and unknown after receiving Shingrix, the patient experienced drug dose administration interval too long. On 25th August 2021, the patient experienced extra dose administered. On an unknown date, the outcome of the extra dose administered and drug dose administration interval too long were unknown. Additional details were reported as follows: The patient received 2nd dose of Shingrix later then the recommended schedule, which led to lengthening of vaccination schedule. The patient also received 3rd dose of Shingrix, which led to extra dose administered. The reporter consented to follow up.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Extra dose administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 1660942

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge 4N2AB

gering
Staat
IL
Alter
-
Geschlecht
U
Eingang
01.09.2021
Impfdatum
01.08.2021
Beginn
01.08.2021
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Incorrect dose administered Product preparation issue

Symptomtext

received Adjuvant (Without the Lyophilized Antigen Component); received Adjuvant (Without the Lyophilized Antigen Component); This case was reported by a other health professional via call center representative and described the occurrence of inappropriate preparation of medication in a patient who received Herpes zoster (Shingrix) (batch number 4N2AB, expiry date 10th February 2023) for prophylaxis. In August 2021, the patient received Shingrix. In August 2021, unknown after receiving Shingrix, the patient experienced inappropriate preparation of medication and inappropriate dose of vaccine administered. On an unknown date, the outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were unknown. Additional details were provided as follows: The age at vaccination was not reported. The clinical coordinator reported that, the patient received the AS01B Adjuvant of Shingrix without lyophilized antigen component, which led to inappropriate preparation of medication and inappropriate dose of vaccine administered. The reporter stated that, 1 patient received only adjuvant of shingrix vaccine. The reporter consented to follow up.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Incorrect dose administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 1533932

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge 4N2ab

gering
Staat
LA
Alter
61,0
Geschlecht
F
Eingang
07.08.2021
Impfdatum
30.07.2021
Beginn
30.07.2021
Tage bis Beginn
0,0
Dosis
2
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Inappropriate schedule of product administration

Symptomtext

shot #1 on 28-Jul-2021/ shot #2 on 30-Jul-2021.; This case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too short in a 61-year-old female patient who received Herpes zoster (Shingrix) (batch number 4N2ab, expiry date 10th February 2023) for prophylaxis. Concomitant products included Herpes zoster (Shingrix). On 30th July 2021, the patient received the 2nd dose of Shingrix .5 ml. On 30th July 2021, unknown after receiving Shingrix, the patient experienced drug dose administration interval too short. On an unknown date, the outcome of the drug dose administration interval too short was unknown. Additional details were provide are as follows: The case was reported by pharmacist. The reporter reported that a patient received 2nd dose of Shingrix 0.5 ml in unknown arm earlier than the recommend interval, which led to shortening of vaccination schedule. The Vaccine Administration Facility was the same as Primary reporter. The reporter consented to follow-up.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Inappropriate schedule of product administration
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 1440476

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge 4N2AB

gering
Staat
MA
Alter
65,0
Geschlecht
M
Eingang
01.07.2021
Impfdatum
01.07.2021
Beginn
01.07.2021
Tage bis Beginn
0,0
Dosis
2
Route/Site
SC / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: unbekannt
Incorrect route of product administration No adverse event

Symptomtext

Second dose of Shingrix vaccine was administered by RN to patient subcutaneously in the left arm instead of intramuscularly in error. Per the CDC "Shingrix should be injected intramuscularly in the deltoid region of the upper arm. Subcutaneous injection is a vaccine administration error and should be avoided. However, if you inadvertently administer Shingrix subcutaneously, that dose is considered valid and does not need to be repeated." Patient was observed for any adverse reaction prior to leaving the clinic. No reaction noted. Patient left clinic in good condition. Patient is aware Shingrix vaccine is up to date. Patient was encouraged to call back the clinic with any signs or symptoms of a reaction.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Incorrect route of product administration
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
None
Vorgeschichte
Hypertension
Andere Medikamente
-
Allergien
None
Vorherige Impfungen
-